17th CSHL Double Helix Medal dinner raises $5.8 million
2022-11-10
疫苗
Cold Spring Harbor Laboratory's annual gala honors Pfizer Chairman & CEO Dr. Albert Bourla and 2020 Nobel laureate Dr. Jennifer Doudna
COLD SPRING HARBOR, N.Y., Nov. 10, 2022 /PRNewswire/ -- On November 9, Cold Spring Harbor Laboratory (CSHL) held its 17th annual Double Helix Medal dinner (DHMD) at the Museum of Natural History in New York City. This year's gala honored Pfizer Chairman and CEO Dr. Albert Bourla and 2020 Nobel laureate Dr. Jennifer A. Doudna. CBS journalist Leslie Stahl returned to emcee the event, which raised a record $5.8 million for biological research.
Continue Reading
Preview
来源: PRNewswire
Left to right: CSHL President and CEO Bruce Stillman, CSHL Board of Trustees Chair Marilyn Simons, and 2022 Double Helix Medal recipients Albert Bourla and Jennifer A. Doudna. Bourla and Doudna were honored for their contributions to genetics research and public health. Image: Sean Zanni / Patrick McMullan Company
Dr. Bourla spearheaded Pfizer's efforts to develop a safe and effective COVID-19 vaccineCOVID-19 vaccine. The company delivered the first FDA-approved vaccine in only eight months. This process usually takes about eight to 10 years. Bourla is now focusing Pfizer's resources across a wide range of therapeutic areas. These include cancer, cardiovascular disease, and inflammatory conditions.
"What excites me the most about Pfizer's impact on global health is the scale," Bourla says. "We are changing patients' lives. We are giving hope to people, hope for science—and that's something that gives us a lot of pride."
Dr. Doudna earned the 2020 Nobel Prize in Chemistry for the development of CRISPR-Cas9. This groundbreaking tool allows scientists to precisely edit DNA. It has revolutionized human and agricultural genetics research. Following CRISPR's widespread adoption, Doudna has emerged as a leading voice on the ethical implications of gene editing.
"When I think about new therapeutics that are only possible using CRISPR technology, I'm thinking about ways that we can not just treat a genetic disorder chronically, but can provide a one-and-done cure," Doudna says. "That's so transformative for patients."
The 2022 DHMD was chaired by Ms. Jamie Nicholls and Mr. O. Francis Biondi, Ms. Barbara Amonson and Dr. Vincent Della Pietra, Drs. Pamela Hurst-Della Pietra and Stephen Della Pietra, Mr. and Mrs. John M. Desmarais, Ms. Elizabeth McCaul and Mr. Francis Ingrassia, Mr. and Mrs. Jeffrey E. Kelter, Dr. and Mrs. Tomislav Kundic, Mr. and Mrs. Robert D. Lindsay, Ms. Ivana Stolnik-Lourie and Dr. Robert Lourie, Dr. and Mrs. Howard L. Morgan, and Drs. Marilyn and James Simons.
Since the inaugural gala in 2006, the DHMD has raised over $55 million to support CSHL's biological research and education programs. Notable past honorees include Muhammad Ali, Kareem Abdul-Jabbar, and Alan Alda.
About Cold Spring Harbor Laboratory
Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,000 people including 600 scientists, students, and technicians. For more information, visit www.cshl.edu
SOURCE Cold Spring Harbor Laboratory
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。